Giant cell tumor of bone (GCTB) is a locally aggressive primary bone neoplasm. In the past decade, the use of denosumab, a humanized monoclonal antibody against RANKL, to treat patients with GCTB has been widely explored. Recent studies have shown that denosumab is highly effective at suppressing the progression of GCTB;
1,2 however, a potential increased risk of local recurrence has been observed when denosumab was used preoperatively, raising concerns on the use of this agent against GCTB in combination with surgery.
3,4 …